In a phase II clinical trial, an FXR agonist called Obeticholic acid (OCA) was found to reduce liver fibrosis in 45% of patients with non-cirrhotic NASH (Neuschwander-Tetri et al., 2015). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.